Early data released from trials of three potential coronavirus vaccines, including a closely watched candidate from Oxford University, increased confidence that a vaccine can train the immune system to recognize and fight Covid-19 without serious side effects.
An experimental coronavirus vaccine being developed by AstraZeneca and the University of Oxford was safe and produced an immune response in early-stage clinical trials, data showed, keeping alive the hope AZD1222 could be in use by the end of 2020.
A Covid-19 vaccine developed by CanSino Biologics and China’s military research unit was shown to be safe and induced immune response in most of the recipients, researchers said.
A dramatic increase in Covid-19 testing and tracing is needed in order to put the United States on a surer path through the pandemic. But that diagnostics increase comes with a significant price tag of about $75 billion from the federal government, the Rockefeller Foundation said in its latest report.
The anti-malaria drug touted by U.S. President Donald Trump as a Covid-19 treatment was ineffective for patients with a mild version of the disease in a study conducted by researchers at the University of Minnesota.
In a study published in Nature Medicine, scientists at Columbia University and Vanderbilt University describe how they were able to successfully restore badly damaged lungs in order to use them for lung transplants.
U.S. industrial conglomerate 3M Co. has partnered with the Massachusetts Institute of Technology to develop a rapid antigen test for COVID-19.
Recently published scientific studies include research into whether Covid-19 immunity might not be possible.
Companies Face Challenge of Enrolling Patients in COVID-19 Vaccine Studies Published: July 6, 2020 By Mark Terry BioSpace As of June 29, there were 13 vaccines against COVID-19 in […]
A global trial designed to test whether the anti-malaria drugs hydroxychloroquine and chloroquine can prevent infection with COVID-19 is to restart after being approved by British regulators.
